HBV相关慢加急性肝衰竭免疫病理发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.030

Abstract

Li Xiaodong, Xu Dongping. Immunopathogenesis of acute-on-chronic hepatitis B liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 317-320.

[1] 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南（2012年版）. 实用肝脏病杂志,2013,16（3）：210-216.
[2] 黄湛镰,高志良. 肝衰竭的三重打击及治疗策略. 内科急危重症杂志,2014,20（3）：154-156.
[3] Atanley,E,van Drunen L,van den Hurk S. Future considerations for dendritic cell immunotherapy against chronic viral infections. Expert Rev Clin Immunol,2014,10（6）:801-813.
[4] Zhang Z,Zou ZS,Fu JL,et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol,2008,49（3）:396-406.
[5] Xing T,Li L,Cao H,et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol,2007,147（1）:184-188.
[6] Busca A,Kumar A. Innate immune responses in hepatitis B virus （HBV） infection. Virol J,2014,11:22.
[7] Schuch A,Hoh A,Thimme R. The role of natural killer cells and CD8（+） T cells in hepatitis B virus infection. Front Immunol,2014,5:258.
[8] Shabani Z,Bagheri M,Zare-Bidaki M,et al. NK cells in hepatitis B virus infection:a potent target for immunotherapy. Arch Virol,2014,159（7）:1555-1565.
[9] Conroy MJ,Mac N R,Grealy R,et al. Circulating CD56 natural killer cells and CD56 T cells that produce interferon-gamma or interleukin-10 are expanded in asymptomatic,E antigen-negative patients with persistent hepatitis B virus infection. J Viral Hepat,2014,doi:10.1111/jvh.12299. [Epub ahead of print].
[10] Kakimi K,Guidotti LG, Koezuka Y,et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med,2000,192（7）:921-930.
[11] Phillips S,Chokshi S,Riva A,et al. CD8（+） T cell control of hepatitis B virus replication:direct comparison between cytolytic and noncytolytic functions. J Immunol,2010,184（1）:287-295.
[12] Koh S,Bertoletti A. Viral hepatitis and serotonin:altering cytotoxic T-lymphocyte function in the liver. Expert Rev Vaccines,2009,8（1）:29-32.
[13] Zhang Z,Zhang JY,Wang LF,et al. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol,2012,27（2）:223-230.
[14] Deng G,Zhou G,Zhai Y,et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology,2004,40（2）:318-326.
[15] Xu Z,Liu Y,Liu L,et al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. Plone One,2013,8（9）:e72799.
[16] Mao WL,Chen Y,Chen YM,et al. Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange. J Clin Gastroenterol,2011,45（6）:551-555.
[17] 赵攀,毕振华,王春亚. 急性肝衰竭患者血清炎性细胞因子水平分析. 实用肝脏病杂志,2014,17（1）：63-64.
[18] Wang K,Wu ZB,Ye YN,et al. Plasma interleukin-10:A likely predictive marker for hepatitis B virus-related acute-on-chronic liver failure. Hepat Mon,2014,14（7）:e19370.
[19] Xu H,Li H,Qu Y,et al. High mobility group box 1 release from cholangiocytes in patients with acute-on-chronic liver failure. Exp Ther Med,2014,8（4）:1178-1184.
[20] Zhang JJ,Fan YC,Zhang ZH,et al. Methylation of suppressor of cytokine signalling 1 gene promoter is associated with acute-on-chronic hepatitis B liver failure. J Viral Hepat,2014,doi:10.1111/jvh.12286. [Epub ahead of print].
[21] Liang XS,Li CZ,Zhou Y,et al. Changes in circulating Foxp3（+） regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure. World J Gastroenterol,2014,20（26）:8558-8571.
[22] Hu X,Ma S,Huang X,et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat,2011,18（7）:458-467.
[23] Zou Z,Li B,Xu D,et al. Imbalanced intrahepatic cytokine expression of interferon-gamma,tumor necrosis factor-alpha,and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol, 2009,43（2）:182-190.
[24] Jin X,Zimmers TA, Perez EA,et al. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair. Hepatology,2006,43（3）:474-484.
[25] Lang PA,Lang KS,Xu HC,et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8 + T-cell immunity. Proc Natl Acad Sci U S A,2012,109（4）:1210-1215.
[26] Waggoner SN,Cornberg M,Selin LK,et al. Natural killer cells act as rheostats modulating antiviral T cells. Nature,2012,481（7381）:394-398.
[27] Cook KD,Whitmire JK. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol,2013,190（2）:641-649.
[28] Li X,Wang Y,Chen Y. Cellular immune response in patients with chronic hepatitis B virus infection. Microb Pathog,2014,74C:59-62.
[29] Francisco LM,Salinas VH,Brown KE,et al. PD-L1 regulates the development,maintenance,and function of induced regulatory T cells. J Exp Med,2009,206（13）:3015-3029.
[30] Radziewicz H,Hanson HL,Ahmed R,et al. Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections:potential for therapeutic application. Gastroenterology,2008,134（7）:2168-2171.
[31] Zhang Z,Zhang JY,Wherry EJ,et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology,2008,134（7）:1938-1949,1949.e1-3.
[32] Liu W,Putnam AL,Xu YZ,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med,2006,203（7）:1701-1711.
[33] Zhou L,Lopes JE,Chong MM,et al. TGF-beta-induced Foxp3 inhibits T（H）17 cell differentiation by antagonizing RORgammat function. Nature,2008,453（7192）:236-240.
[34] Dong X,Gong Y,Zeng H,et al. Imbalance between circulating CD4 + regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. Liver Int,2013,33（10）:1517-1526.
[35] Niu YH,Yin DL,Liu HL,et al. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure. World J Gastroenterol,2013,19（26）:4146-4154.

Immunopathogenesis of acute-on-chronic hepatitis B liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.